EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

No Evidence of Metabolomic Disruptions From Real‐World Intakes of Aspartame or Saccharin: The Coronary Artery Risk Development in Young Adults Study

Brian T Steffen iD, Elizabeth R Lusczek, David R Jacobs, Chi Chen, Venkatesh L Murthy, Linda Van Horn, James G Terry, John Jeffrey Carr, Lyn M Steffen

Journal of Diabetes · 2025

DOI: 10.1111/1753-0407.70138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabetes, 2025. Verfasst von Brian T Steffen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Computational Health Sciences, Department of Surgery, University of Minnesota School of Medicine, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Aspartame, Saccharin, Metabolomics, Sweetening Agents. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute (NHLBI), Northwestern University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Artificial sweeteners have become ubiquitous additives in the food supply, and yet the safety of their regular consumption remains controversial. The present study examined whether intakes of aspartame or saccharin are related to aberrations in the plasma metabolome indicating disruptions in metabolism.

Methods

A cohort of 2160 male and female participants, mean age 32.1 years, was included in the analysis. Liquid chromatography and mass‐spectrometry assessed 549 unique plasma metabolites. Diet was assessed using a validated questionnaire that allowed for estimation of aspartame and saccharin intakes. A generalized linear regression model evaluated associations of saccharin or aspartame intake with plasma metabolites with adjustment for potential confounders and multiple comparisons. Multiple sensitivity analyses and propensity score matching were conducted.

Results

Heavy aspartame intake (≥ 5 servings/day) was associated with plasma levels (per SD) of saccharin ( β = 0.90; q = 9.0E‐36), myo‐inositol ( β = 0.27; q = 3.7E‐04), caffeine ( β = 0.31; q = 4.1E‐04), and five metabolites of caffeine including 1,7‐dimethyluric acid ( β = 0.37; q = 7.1E‐06), 1‐methylurate ( β = 0.36; q = 7.1E‐06), 5‐acetylamino‐6‐amino‐3‐methyluracil ( β = 0.38; q = 3.2E‐6), theophylline ( β = 0.36; q = 9.1E‐06), and 1‐methylxanthine ( β = 0.32; q = 2.0E‐03). Saccharin intake was associated with plasma levels of saccharin alone ( β = 0.29; q = 1.8E‐10). No associations with sugars, carbohydrates, lipids, amino acids, or other metabolites that would suggest metabolic perturbations were observed with either artificial sweetener; sensitivity analyses supported these findings.

Conclusions

In the largest metabolomics study to date, no link was found between metabolic disruptions and either aspartame or saccharin intake. We cannot exclude the possibility that more extreme intakes may be related to metabolic disruptions among consumers of artificial sweeteners.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspartameSaccharinMetabolomicsSweetening AgentsMetabolomeHumansFemaleMaleAdultYoung AdultRisk Factors

Stichwörter der Autor:innen

artificial sweetenersaspartamedietmetabolomicssaccharin

Substanzen

AspartameSaccharinSweetening Agents

Autor:innen und Institutionen

  • Division of Computational Health Sciences, Department of Surgery, University of Minnesota School of Medicine, Minneapolis, Minnesota, USA.
  • Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Food Science and Nutrition, University of Minnesota, St. Paul, Minnesota, USA.
  • Departments of Medicine and Radiology, University of Michigan, Ann Arbor, Michigan, USA.
  • Nutrition Division, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University in Chicago, Chicago, Illinois, USA.
  • Department of Radiology and Vanderbilt Translational and Clinical Cardiovascular Research Center (VTRACC), Vanderbilt University Medical Center, Nashville, Tennessee, USA.

ORCID-Profile: Brian T Steffen

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute (NHLBI)
  • Northwestern University
  • University of Minnesota

Zitieren

APA

Steffen, B. T., Lusczek, E. R., Jacobs, D. R., Chen, C., Murthy, V. L., Van Horn, L., Terry, J. G., Carr, J. J., & Steffen, L. M. (2025). No Evidence of Metabolomic Disruptions From Real‐World Intakes of Aspartame or Saccharin: The Coronary Artery Risk Development in Young Adults Study. Journal of Diabetes. https://doi.org/10.1111/1753-0407.70138

Vancouver

Steffen BT, Lusczek ER, Jacobs DR, Chen C, Murthy VL, Van Horn L, et al. No Evidence of Metabolomic Disruptions From Real‐World Intakes of Aspartame or Saccharin: The Coronary Artery Risk Development in Young Adults Study. Journal of Diabetes. 2025. doi:10.1111/1753-0407.70138

BibTeX
@article{Steffen2025,
  author = {Steffen, Brian T and Lusczek, Elizabeth R and Jacobs, David R and Chen, Chi and Murthy, Venkatesh L and Van Horn, Linda and Terry, James G and Carr, John Jeffrey and Steffen, Lyn M},
  title = {No Evidence of Metabolomic Disruptions From Real‐World Intakes of Aspartame or Saccharin: The Coronary Artery Risk Development in Young Adults Study},
  journal = {Journal of Diabetes},
  year = {2025},
  doi = {10.1111/1753-0407.70138}
}
Kostenlos starten →